Clinical Results of Secondary Hormonal Treatment

  • Jae Young ParkEmail author


Prostate cancer (PCa) is one of the leading malignant causes of death in men globally, with an incidence of 1,095,000 new cases diagnosed each year causing 307,000 cancer-specific deaths in 2012 [1]. Many patients with PCa can be cured with local treatments, but approximately one-third of them will ultimately become a progressive disease, which will be characterized by increasing prostate-specific antigen (PSA) levels. Androgen deprivation therapy (ADT) including surgical or medical castration has been regarded as primary systemic therapy for metastatic PCa for more than 50 years. Surgical castration is the traditional treatment option which means bilateral orchiectomy. Nowadays, medical castration with gonadotropin-releasing hormone (GnRH) analogues and/or antiandrogen which suppresses testosterone production is the most common option in primary ADT.


  1. 1.
    IARC: GLOBOCAN. In: International Agency for Research on Cancer, 2012.
  2. 2.
    Lam JS, Leppert JT, Vemulapalli SN, Shvarts O, Belldegrun AS. Secondary hormonal therapy for advanced prostate cancer. J Urol. 2006;175(1):27–34.CrossRefPubMedGoogle Scholar
  3. 3.
    Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351(15):1513–20.CrossRefPubMedGoogle Scholar
  4. 4.
    Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502–12.CrossRefPubMedGoogle Scholar
  5. 5.
    Gregory CW, Johnson RT, Mohler JL, French FS, Wilson EM. Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res. 2001;61(7):2892–8.PubMedGoogle Scholar
  6. 6.
    Molina A, Belldegrun A. Novel therapeutic strategies for castration resistant prostate cancer: inhibition of persistent androgen production and androgen receptor mediated signaling. J Urol. 2011;185(3):787–94.CrossRefPubMedGoogle Scholar
  7. 7.
    Jackson E Jr, Pandey P, Seaver LE, Feliz TP. Prostate specific antigen after gonadal androgen withdrawal and deferred flutamide treatment. J Urol. 1995;154(2):448–53.CrossRefGoogle Scholar
  8. 8.
    Fossa S, Slee PT, Brausi M, Horenblas S, Hall R, Hetherington J, et al. Flutamide versus prednisone in patients with prostate cancer symptomatically progressing after androgen-ablative therapy: a phase III study of the European organization for research and treatment of cancer genitourinary group. J Clin Oncol. 2001;19(1):62–71.CrossRefPubMedGoogle Scholar
  9. 9.
    Debruyne FJ, Murray R, Fradet Y, Johansson JE, Tyrrell C, Boccardo F, et al. Liarozole—a novel treatment approach for advanced prostate cancer: results of a large randomized trial versus cyproterone acetate. Urology. 1998;52(1):72–81.CrossRefPubMedGoogle Scholar
  10. 10.
    Desai A, Stadler WM, Vogelzang NJ. Nilutamide: possible utility as a second-line hormonal agent. Urology. 2001;58(6):1016–20.CrossRefPubMedGoogle Scholar
  11. 11.
    Joyce R, Fenton MA, Rode P, Constantine M, Gaynes L, Kolvenbag G, et al. High dose bicalutamide for androgen independent prostate cancer: effect of prior hormonal therapy. J Urol. 1998;159(1):149–53.CrossRefPubMedGoogle Scholar
  12. 12.
    Kassouf W, Tanguay S, Aprikian AG. Nilutamide as second line hormone therapy for prostate cancer after androgen ablation fails. J Urol. 2003;169(5):1742–4.CrossRefPubMedGoogle Scholar
  13. 13.
    Kucuk O, Fisher E, Moinpour CM, Coleman D, Hussain MH, Sartor AO, et al. Phase II trial of bicalutamide in patients with advanced prostate cancer in whom conventional hormonal therapy failed: a Southwest Oncology Group study (SWOG 9235). Urology. 2001;58(1):53–8.CrossRefPubMedGoogle Scholar
  14. 14.
    Scher HI, Liebertz C, Kelly WK, Mazumdar M, Brett C, Schwartz L, et al. Bicalutamide for advanced prostate cancer: the natural versus treated history of disease. J Clin Oncol. 1997;15(8):2928–38.CrossRefPubMedGoogle Scholar
  15. 15.
    Kelly WK, Scher HI. Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome. J Urol. 1993;149(3):607–9.CrossRefPubMedGoogle Scholar
  16. 16.
    Scher HI, Kelly WK. Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. J Clin Oncol. 1993;11(8):1566–72.CrossRefPubMedGoogle Scholar
  17. 17.
    Suzuki H, Okihara K, Miyake H, Fujisawa M, Miyoshi S, Matsumoto T, et al. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade. J Urol. 2008;180(3):921–7.CrossRefPubMedGoogle Scholar
  18. 18.
    Small EJ, Halabi S, Dawson NA, Stadler WM, Rini BI, Picus J, et al. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol. 2004;22(6):1025–33.CrossRefPubMedGoogle Scholar
  19. 19.
    Chen R-J, Lee W-S, Liang Y-C, Lin J-K, Wang Y-J, Lin C-H, et al. Ketoconazole induces G0/G1 arrest in human colorectal and hepatocellular carcinoma cell lines. Toxicol Appl Pharmacol. 2000;169(2):132–41.CrossRefPubMedGoogle Scholar
  20. 20.
    Rochlitz C, Damon L, Russi M, Geddes A, Cadman E. Cytotoxicity of ketoconazole in malignant cell lines. Cancer Chemother Pharmacol. 1988;21(4):319–22.CrossRefPubMedGoogle Scholar
  21. 21.
    Lo EN, Beckett LA, Pan C-X, Robles D, Suga JM, Sands JM, et al. Prospective evaluation of low-dose ketoconazole plus hydrocortisone in docetaxel pre-treated castration-resistant prostate cancer patients. Prostate Cancer Prostatic Dis. 2015;18(2):144–8.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Figg WD, Liu Y, Arlen P, Gulley J, Steinberg SM, Liewehr DJ, et al. A randomized, phase II trial of ketoconazole plus alendronate versus ketoconazole alone in patients with androgen independent prostate cancer and bone metastases. J Urol. 2005;173(3):790–6.CrossRefPubMedGoogle Scholar
  23. 23.
    Kruit W, Stoter G, Klijn J. Effect of combination therapy with aminoglutethimide and hydrocortisone on prostate-specific antigen response in metastatic prostate cancer refractory to standard endocrine therapy. Anti-Cancer Drugs. 2004;15(9):843–7.CrossRefPubMedGoogle Scholar
  24. 24.
    Almassi N, Reichard C, Li J, Russell C, Perry J, Ryan CJ, et al. HSD3B1 and response to a nonsteroidal CYP17A1 inhibitor in castration-resistant prostate cancer. JAMA Oncol. 2017;Google Scholar
  25. 25.
    Tannock I, Gospodarowicz M, Meakin W, Panzarella T, Stewart L, Rider W. Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response. J Clin Oncol. 1989;7(5):590–7.CrossRefPubMedGoogle Scholar
  26. 26.
    Kantoff PW, Halabi S, Conaway M, Picus J, Kirshner J, Hars V, et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol. 1999;17(8):2506–13.CrossRefPubMedGoogle Scholar
  27. 27.
    Small EJ, Meyer M, Marshall ME, Reyno LM, Meyers FJ, Natale RB, et al. Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone. J Clin Oncol. 2000;18(7):1440–50.CrossRefPubMedGoogle Scholar
  28. 28.
    Storlie JA, Buckner JC, Wiseman GA, Burch PA, Hartmann LC, Richardson RL. Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone-refractory metastatic prostate carcinoma. Cancer. 1995;76(1):96–100.CrossRefPubMedGoogle Scholar
  29. 29.
    Robertson CN, Roberson KM, Padilla GM, O'Brien ET, Cook JM, Kim C-S, et al. Induction of apoptosis by diethylstilbestrol in hormone-insensitive prostate cancer cells. JNCI. 1996;88(13):908–17.CrossRefPubMedGoogle Scholar
  30. 30.
    Scherr DS, Pitts WR. The nonsteroidal effects of diethylstilbestrol: the rationale for androgen deprivation therapy without estrogen deprivation in the treatment of prostate cancer. J Urol. 2003;170(5):1703–8.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2018

Authors and Affiliations

  1. 1.Department of UrologyKorea University Ansan Hospital, Korea University College of MedicineAnsanSouth Korea

Personalised recommendations